ClinicalTrialsFinder

Treatment With Second-generation Bruton's Tyrosine Kinase Inhibitors (Acalabrutinib, Zanubrutinib) Clinical Trials in Dijon

1 recruitingDijon, France

Showing 1–1 of 1 trials

Recruiting

Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study

Treatment With Second-generation Bruton's Tyrosine Kinase Inhibitors (Acalabrutinib, Zanubrutinib)
Centre Hospitalier Universitaire Dijon100 enrolled1 locationNCT07174141